Cape Investment Advisory’s Syndax Pharmaceuticals SNDX Stock Holding History

Cape Investment Advisory’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$81.1K	Buy	+3,709	New	+$77.1K	0.02%	381
2026 Q1	–	Sell	-4,663	Closed	-$98K	–	1044
2025 Q4	$98K	Sell	4,663 -1,778	-28%	-$31K	0.03%	307
2025 Q3	$99.1K	Buy	6,441 +14	+0.2%	+$183	0.1%	164
2025 Q2	$60.2K	Hold	6,427	–	–	0.02%	346
2025 Q1	$79K	Hold	6,427	–	–	0.03%	282
2024 Q4	$85K	Buy	6,427 +3,927	+157%	+$67.2K	0.03%	260
2024 Q3	$48.1K	Buy	+2,500	New	+$51.6K	0.02%	325

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Cape Investment Advisory's SNDX Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 3,709 shares worth $81.1K. The stake represents 0.02% of the portfolio and ranks #381 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in SNDX as recently as Q4 2025.

Cape Investment Advisory first reported a position in SNDX in Q3 2024 and has held it in 7 quarters since. The position peaked at $99.1K in Q3 2025. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Cape Investment Advisory held 3,709 shares of Syndax Pharmaceuticals worth $81.1K as of Q2 2026.
Syndax Pharmaceuticals was a new Cape Investment Advisory position in Q2 2026.
Syndax Pharmaceuticals made up 0.02% of Cape Investment Advisory's portfolio in Q2 2026, its #381 holding.
Cape Investment Advisory first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
Cape Investment Advisory's Syndax Pharmaceuticals position peaked at $99.1K in Q3 2025.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.